Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10238	Companies
211363	Keywords
141296	Articles
111973	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 9 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 9 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 9 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 1 year 10 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 1 year 10 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 1 year 10 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 1 year 10 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 1 year 10 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 1 year 10 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 1 year 10 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 04/18/2026 at 04:00, 13 hours 3 minutes ago

Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Published on 04/18/2026 at 02:00, 15 hours 3 minutes ago

AI/ML Innovations Announces Completion of Share Issuance
Published on 04/18/2026 at 01:35, 15 hours 28 minutes ago

Medicure Announces Resignation of President and Chief Operating Officer
Published on 04/18/2026 at 01:00, 16 hours 3 minutes ago

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Published on 04/18/2026 at 00:00, 17 hours 3 minutes ago

Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia

View all ACCESSWIRE

EQS Group

Published on 04/18/2026 at 00:05, 16 hours 57 minutes ago

ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Published on 04/17/2026 at 20:33, 20 hours 29 minutes ago

LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Published on 04/17/2026 at 19:35, 21 hours 28 minutes ago

Stabilisation Notice
Published on 04/17/2026 at 19:30, 21 hours 32 minutes ago

KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS
Published on 04/17/2026 at 19:29, 21 hours 33 minutes ago

EQS-Adhoc: KAP AG: KAP AG: REFINANCING CONCEPT AGREED; TERM OF EXISTING SYNDICATED LOAN EXTENDED BY THREE YEARS

Les Echos

Published on 04/17/2026 at 19:00, 22 hours 3 minutes ago

Cegedim: Release of its 2025 Universal Registration Document
Published on 04/17/2026 at 17:45, 23 hours 18 minutes ago

Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Published on 04/17/2026 at 15:26, 1 day 1 hour ago

Statement about the number of shares composing the share capital and the number of voting rights as of March 31, 2026
Published on 04/17/2026 at 09:10, 1 day 7 hours ago

Number of shares and voting rights - March 2026 (In French only)
Published on 04/16/2026 at 18:02, 1 day 23 hours ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026

View all LES ECHOS COMFI WIRE